Design strategies for positively charged endolysins: Insights into Artilysin development

Autor/a

Carratalá, Jose Vicente

Alomar, Oscar

Garcia-Fruitos, Elena

Ferrer-Miralles, Neus

Fecha de publicación

2023-09-06



Resumen

Endolysins are bacteriophage-encoded enzymes that can specifically degrade the peptidoglycan layer of bacterial cell wall, making them an attractive tool for the development of novel antibacterial agents. The use of genetic engineering techniques for the production and modification of endolysins offers the opportunity to customize their properties and activity against specific bacterial targets, paving the way for the development of personalized therapies for bacterial infections. Gram-negative bacteria possess an outer membrane that can hinder the action of recombinantly produced endolysins. However, certain endolysins are capable of crossing the outer membrane by virtue of segments that share properties resembling those of cationic peptides. These regions increase the affinity of the endolysin towards the bacterial surface and assist in the permeabilization of the membrane. In order to improve the bactericidal effectiveness of endolysins, approaches have been implemented to increase their net charge, including the development of Artilysins containing positively charged amino acids at one end. At present, there are no specific guidelines outlining the steps for implementing these modifications. There is an ongoing debate surrounding the optimal location of positive charge, the need for a linker region, and the specific amino acid composition of peptides for modifying endolysins. The aim of this study is to provide clarity on these topics by analyzing and comparing the most effective modifications found in previous literature.

Tipo de documento

Artículo

Versión del documento

Versión publicada

Lengua

Inglés

Materias CDU

579 - Microbiología

Páginas

14

Publicado por

Elsevier

Es versión de

Biotechnology Advances

Número del acuerdo de la subvención

MICIU/Programa Estatal de generación del conocimiento y fortalecimiento científico y tecnológico del sistema I+D+I y Programa Estatal de I+D+I orientada a los retos de la sociedad/PID2019-107298RB-C21/ES/PRODUCCION Y VALIDACION DE FARMACOS BASADOS EN PEPTIDOS DE DEFENSA DEL HUESPED PARA EL TRATAMIENTO DEL SINDROME RESPIRATORIO BOVINO/

MICIU/Programa Estatal de generación del conocimiento y fortalecimiento científico y tecnológico del sistema I+D+I y Programa Estatal de I+D+I orientada a los retos de la sociedad/PID2019-107298RB-C22/ES/ /

Derechos

Attribution-NonCommercial 4.0 International

Attribution-NonCommercial 4.0 International

Este ítem aparece en la(s) siguiente(s) colección(ones)